Document Detail


NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.
MedLine Citation:
PMID:  23028738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The new molecular entity quinoxalinhydrazide derivative NVX-412 was identified as a promising drug candidate for the treatment of various cancer types due to its strong cytotoxic activity and relative specificity. Here, we provide first data about the mechanisms of action of NVX-412. We show that NVX-412 exerts its anti-neoplastic activity in a p53-independent manner and induces S-phase arrest and DNA damage as assessed by γH2AX staining. We suggest a bi-modal (dose-dependent) mode of action of NVX-412, being primarily cytostatic at lower and predominantly cytotoxic at higher concentrations. Based on the broad and consistent anti-neoplastic activity observed, NVX-412 holds promise as an effective drug candidate for the treatment of various cancer types, especially for hematological malignancies with highly unmet medical need.
Authors:
Alexandra Hebar; Barbara C Rütgen; Edgar Selzer
Related Documents :
23221098 - Carrier-free, functionalized pure drug nanorods as a novel cancer-targeted drug deliver...
702728 - Impairment of hemostasis in patients with severe hemophilia. failure of diphenhydramine...
24146498 - Chemotherapeutic activities of carthami flos and its reversal effect on multidrug resis...
115258 - Prostaglandins, rheumatoid arthritis, fibrin and lymphoedema.
12404618 - Quantitative eeg methods and measures in human psychopharmacological research.
15077928 - K562 cell sensitization to 5-fluorouracil- or interferon-alpha-induced apoptosis via co...
Publication Detail:
Type:  Journal Article     Date:  2012-09-13
Journal Detail:
Title:  PloS one     Volume:  7     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-02     Completed Date:  2013-02-26     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e45015     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / chemistry,  pharmacology*,  therapeutic use*
Cell Line, Tumor
Cell Shape / drug effects
Cell Size / drug effects
DNA Damage*
DNA Replication / drug effects
Drug Screening Assays, Antitumor
Humans
Hydrazines / chemistry,  pharmacology*,  therapeutic use*
Inhibitory Concentration 50
Neoplasms / drug therapy*,  pathology*
Phosphorylation / drug effects
Quinoxalines / chemistry,  pharmacology*,  therapeutic use*
S Phase Cell Cycle Checkpoints / drug effects*
Tumor Markers, Biological / metabolism
Tumor Suppressor Protein p53 / metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Hydrazines; 0/Quinoxalines; 0/Tumor Markers, Biological; 0/Tumor Suppressor Protein p53; 0/pyrazine-2-carboxylic acid N'- (7-fluoropyrrolo(1,2-a)quinoxalin-4-yl)-hydrazide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The diversity and biogeography of Western Indian Ocean reef-building corals.
Next Document:  Trail pheromone of the Argentine ant, Linepithema humile (Mayr) (Hymenoptera: Formicidae).